

# UC Berkeley

## UC Berkeley Previously Published Works

### Title

Assessing computational predictions of the phenotypic effect of cystathionine-beta-synthase variants

### Permalink

<https://escholarship.org/uc/item/5jc5662r>

### Journal

Human Mutation, 40(9)

### ISSN

1059-7794

### Authors

Kasak, Laura  
Bakolitsa, Constantina  
Hu, Zhiqiang  
[et al.](#)

### Publication Date

2019-09-01

### DOI

10.1002/humu.23868

Peer reviewed



Published in final edited form as:

*Hum Mutat.* 2019 September ; 40(9): 1530–1545. doi:10.1002/humu.23868.

## Assessing Computational Predictions of the Phenotypic Effect of Cystathionine-beta-Synthase Variants

Laura Kasak<sup>1,2</sup>, Constantina Bakolitsa<sup>1</sup>, Zhiqiang Hu<sup>1</sup>, Changhua Yu<sup>1</sup>, Jasper Rine<sup>3</sup>, Dago F. Dimster-Denk<sup>3,\*</sup>, Gaurav Pandey<sup>1,\*</sup>, Greet De Baets<sup>4,5</sup>, Yana Bromberg<sup>6</sup>, Chen Cao<sup>7,8</sup>, Emidio Capriotti<sup>9,\*</sup>, Rita Casadio<sup>10</sup>, Joost Van Durme<sup>4,11</sup>, Manuel Giollo<sup>12</sup>, Rachel Karchin<sup>13</sup>, Panagiotis Katsonis<sup>14</sup>, Emanuela Leonardi<sup>15,\*</sup>, Olivier Lichtarge<sup>14</sup>, Pier Luigi Martelli<sup>10</sup>, David Masica<sup>13,\*</sup>, Sean D. Mooney<sup>16,\*</sup>, Ayodeji Olatubosun<sup>17</sup>, Lipika R. Pal<sup>7</sup>, Predrag Radivojac<sup>18</sup>, Frederic Rousseau<sup>4,5</sup>, Castrense Savojardo<sup>10</sup>, Joost Schymkowitz<sup>4,5</sup>, Janita Thusberg<sup>16,\*</sup>, Silvio C.E. Tosatto<sup>12</sup>, Mauno Vihinen<sup>17,\*</sup>, Jouni Väliäho<sup>17</sup>, Susanna Repo<sup>1,\*</sup>, John Mout<sup>5,19</sup>, Steven E. Brenner<sup>1</sup>, Iddo Friedberg<sup>20,21,\*</sup>

<sup>1</sup>Department of Plant and Microbial Biology, University of California, Berkeley, CA, USA <sup>2</sup>Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia <sup>3</sup>California Institute for Quantitative Biosciences, University of California, Berkeley, CA, USA <sup>4</sup>Switch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium <sup>5</sup>Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium <sup>6</sup>Department of Biochemistry and Microbiology, Rutgers University, New Brunswick, NJ, USA <sup>7</sup>Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA <sup>8</sup>Computational Biology, Bioinformatics and Genomics, Biological Sciences Graduate Program, University of Maryland, College Park, MD, USA <sup>9</sup>Department of Bioengineering, Stanford University, Stanford, CA, USA <sup>10</sup>Biocomputing Group, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy <sup>11</sup>Vrije Universiteit Brussel, Brussels, Belgium <sup>12</sup>Department of Biomedical Sciences, University of Padua, Padua, Italy <sup>13</sup>Department of Biomedical Engineering and Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD, USA <sup>14</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA <sup>15</sup>Department for Woman and Child Health, University of Padua, Italy <sup>16</sup>Buck Institute for Research on Aging, Novato, CA, USA <sup>17</sup>Institute of Medical Technology, University of Tampere, Tampere, Finland <sup>18</sup>School of Informatics

**Correspondence:** Iddo Friedberg, Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA USA, idoerg@iastate.edu.

\*Present address: Dago F. Dimster-Denk, Pionyr Immunotherapeutics, San Francisco, CA, USA; Gaurav Pandey, Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Emidio Capriotti, BioFOLD Group, Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy; Emanuela Leonardi, Department for Woman and Child Health, University of Padua, Italy; Pediatric Research Institute, Citta della Speranza, Padua, Italy; David Masica, AbbVie Inc., Redwood City, CA, USA; Sean D. Mooney, Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA; Predrag Radivojac, Khoury College of Computer Sciences, Northeastern University, Boston MA, USA; Mauno Vihinen, Department of Experimental Medical Science, Lund University, Lund, Sweden; Janita Thusberg, Invitae, San Francisco, CA, USA; Susanna Repo, ELIXIR, Wellcome Genome Campus, Hinxton, Cambridge, UK; Iddo Friedberg, Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, USA

*Disclosure statement:* The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available to registered users from the CAGI web site <https://genomeinterpretation.org/content/cagi-2011-results>.

and Computing, Indiana University, Bloomington, IN, USA <sup>19</sup>Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD, USA <sup>20</sup>Department of Microbiology, Miami University, Oxford, OH, USA <sup>21</sup>Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA USA

## Abstract

Accurate prediction of the impact of genomic variation on phenotype is a major goal of computational biology and an important contributor to personalized medicine. Computational predictions can lead to a better understanding of the mechanisms underlying genetic diseases, including cancer, but their adoption requires thorough and unbiased assessment. Cystathionine-beta-synthase (CBS) is an enzyme that catalyzes the first step of the transsulfuration pathway, from homocysteine to cystathionine, and in which variations are associated with human hyperhomocysteinemia and homocystinuria. We have created a computational challenge under the CAGI framework to evaluate how well different methods can predict the phenotypic effect(s) of CBS single amino acid substitutions using a blinded experimental data set. CAGI participants were asked to predict yeast growth based on the identity of the mutations. The performance of the methods was evaluated using several metrics. The CBS challenge highlighted the difficulty of predicting the phenotype of an *ex vivo* system in a model organism when classification models were trained on human disease data. We also discuss the variations in difficulty of prediction for known benign and deleterious variants, as well as identify methodological and experimental constraints with lessons to be learned for future challenges.

## Keywords

CAGI challenge; cystathionine-beta-synthase; single amino acid substitution; critical assessment; phenotype prediction; machine learning

## INTRODUCTION

One of the central challenges in biology is to determine the impact of genomic variation on the phenotype(s) of an organism. As the amount of genomic data increases and accumulates at an exponential rate, comprehensive and accurate prediction algorithms are needed when biological experiments are expensive or difficult to execute (Fernald, Capriotti, Daneshjou, Karczewski, & Altman, 2011). Missense mutations are the most studied class of protein-altering variants; however, even today the algorithms often disagree on the pathogenicity prediction of the variants (Ioannidis et al., 2016). To determine the optimal use of each algorithm in different tasks, a thorough and unbiased methodological assessment is required. The ultimate aim is to attain a better understanding of the complex genotype-phenotype relationship, and, most importantly, provide the basis for clinical application to improve human health (Rost, Radivojac, & Bromberg, 2016). Since 2010, the Critical Assessment of Genome Interpretation (CAGI) experiment has been seeking to address these needs by evaluating bioinformatics tools developed for phenotype prediction from genomic variation data (Hoskins et al., 2017).

Cystathionine-beta-synthase (CBS, MIM# 613381) is an extensively studied vitamin-dependent enzyme involved in cysteine biosynthesis via the transsulfuration pathway. The molecular architecture of human CBS comprises an N-terminal heme-binding domain (residues 1–70), followed by the catalytic domain (residues 71–381) and a C-terminal regulatory domain (residues 412–551) (Majtan et al., 2018). The heme domain, which is found only in mammalian forms of CBS, lacks any significant structural elements and exhibits significant sequence diversity. Changes in the heme's coordination environment can be transmitted to the active site ~20 Å away, leading to inhibition of CBS activity (Weeks, Singh, Madzlan, Banerjee, & Spiro, 2009). The central domain belongs to the family of pyridoxal-5'-phosphate (PLP)-dependent enzymes, with the PLP cofactor bound via a Schiff base to K119 in the CBS active site. The C-terminal domain, also known as the Bateman module, contains two consecutive CBS-motifs (residues 412–471 and 477–551) that form distinct binding sites for S-adenosyl-methionine (AdoMet) and enable CBS homotetramerization. Two high-affinity and four low-affinity AdoMet binding sites have been identified per CBS tetramer, with distinct roles proposed in the regulation and activation (Pey, Majtan, Sanchez-Ruiz, & Kraus, 2013). Catalytic and regulatory domains are joined by a flexible linker (residues 382–411) that is sensitive to proteolysis. Targeted proteolysis of CBS results in a truncated, dimeric and more active form of the enzyme, adding another layer of CBS regulation (Skovby, Kraus, & Rosenberg, 1984; Zou & Banerjee, 2003).

Homocystinuria due to CBS deficiency (MIM# 236200) is an autosomal recessive inborn error of sulfur amino acid metabolism, characterized by increased levels of homocysteine in the urine (Mudd, Levy, & Kraus, 2001), myopia, osteoporosis, or other skeletal abnormalities. The estimated worldwide prevalence of homocystinuria is approximately 1 in 100,000 (Moorthie, Cameron, Sagoo, Bonham, & Burton, 2014). More than 160 different disease-associated variants have been identified in the *CBS* gene (<http://cbs.lf1.cuni.cz/index.php>). The majority of these are substitutions that do not involve catalytic residues, suggesting that their effect resides in structural or conformational perturbations leading to a misfolded protein (Majtan et al., 2018). About one-half of homocystinuric patients respond to high doses of pyridoxine, the soluble form of PLP (Mudd et al., 2001) and several mutations are clearly pyridoxine remediable (B6-responsive homocystinuria): p.A114V, p.R266K, p.R369H, p.K384E, p.L539S, and the most common substitution p.I278T, which accounts for ~20% of all homocystinuric alleles (Dimster-Denk, Tripp, Marini, Marqusee, & Rine, 2013; Moat et al., 2004; Skovby, Gaustadnes, & Mudd, 2010).

Since CBS is well studied and its *ex-vivo* mutation effects are easily quantified, it is a tractable system for investigating phenotype - genotype relationships, making it an attractive target for the CAGI challenges. Here we present an assessment of computational predictions on the effects of single amino acid substitutions in the function of CBS. In the CAGI1 (2010) CBS challenge, participants were asked to predict yeast growth rates when compared with wild-type yeast based on amino acid substitution information. This dataset comprised 51 synthetic single amino acid substitutions within the human CBS coding region. In the CAGI 2 (2011) CBS challenge, a larger set of variants (78 amino acid substitutions) that had been observed in patients with homocystinuria was provided for the predictors. In both challenges, participants were asked to submit predictions on the effect of the variants in the

function of CBS at high (400 ng/ml) and low (2 ng/ml) cofactor (pyridoxine) concentration. Both CBS predictions were blinded experiments. At the time these challenges took place, the experimental effects of the mutations had not yet been published. Altogether, 38 predictions from CAGI1 and CAGI2 were assessed. Methods employed varied from the purely structural to ones combining both structural and sequence conservation information or annotation, and from meta-predictors (models that use the predictions of other methods as features) to methods driven mainly by sequence, while one submission was a set of random predictions.

In general, deleterious mutations were better predicted than variants with minor or no effects on phenotype, with the hardest to predict effects often involving variants with weak sequence and structural signals. The use of distinct assessment criteria revealed differences in performance between methods, with methods integrating sequence, structure and functional features performing best overall.

## METHODS

### Dataset

The CAGI1 CBS challenge included 51 synthetic single amino acid substitutions within the human CBS (Table 1), while the CAGI2 CBS challenge included 78 single amino acid variants that had been observed in patients with homocystinuria. The experimental data used in CAGI1 and CAGI2 were published after the challenges were closed by Dimster-Denk et al., 2013 and Mayfield et al., 2012 respectively. Only one variant, p.N228K, overlapped between CAGI1 and CAGI2. In addition, four positions (p.H65, p.L154, p.V354, p.V371) overlap between the two challenges but the amino acid substitutions are different. The variant nomenclature refers to the human CBS cDNA (Refseq NM\_000071.2).

The functionality of the variants was tested in an *in vivo* yeast complementation assay, where the human *CBS* allele is expressed in yeast and functionally complements the yeast ortholog, *CYS4*, which was removed from the chromosome. In this assay, growth is dependent upon the level of mutant human CBS function, and growth rates are expressed as a percentage relative to wild type grown with the same amount of exogenous pyridoxine supplementation. An experimental standard deviation is also available based on 3–4 repeated assays. The assay was performed in the presence of high (400 ng/ml) and low (2 ng/ml) pyridoxine concentrations. For a detailed description of this assay, see Mayfield et al. (2012) and Dimster-Denk et al. (2013). Participants were asked to submit predictions on the effect of the variants on the function of CBS both in high and low pyridoxine concentrations. The submitted prediction was requested as the percent of growth when compared with wild-type yeast, with a standard deviation. The predictions were then assessed against the percent of growth values actually measured for each substitution in the yeast assay.

### Prediction assessment

The correlation between the predicted effect of the mutations and the actual effects serves as an initially simple but powerful measure to assess the accuracy of the prediction methods. Because the mutation data are not derived from a normal distribution, nonparametric tests

were used to assess the methods. Both Spearman's rank correlation and Kendall's Tau correlation (KCC) were used to assess each algorithm's predictions against the observed growth rates. The root-mean-square deviation (RMSD) was also calculated to estimate the difference between experimental and predicted values. In order to assess the accuracy of the algorithms in a clinical sense, evaluation was also conducted against a binary version of the experimental growth rates. A threshold of 0 was chosen for the binary version and the performance was evaluated in terms of area under the ROC curve (AUC), sensitivity, specificity, accuracy, and positive/negative predictive value (Lever, Krzywinski, & Altman, 2016). For experimental data, the total number of negatives (no growth substitutions) were defined as  $N=TN+FP$  and the total number of experimental positives (growth detected) as  $P=TP+FN$ . All the performance indices are shown in Supp. Table S1. An overall ranking of the methods was defined as a mean ranking of three different measures (KCC, AUC, and RMSD) shown in Supp. Table S2. These three measures were chosen since they assess complementary aspects of prediction performance.

### Bootstrapping

To assess the robustness of our comparison of different prediction models, and to identify any possible performance bias generated by outliers, we performed bootstrap simulation on measurements. 10,000 random samples were generated using sampling with replacement of the experimental data. The resulting evaluation metrics (KUC, AUC and RMSD) were plotted as bar plots with error bars representing one standard deviation below and above the mean value for each metric generated through iterations of bootstrap sampling of data-points.

To estimate the statistical significance of pairwise prediction comparisons, we applied bootstrap simulation (as described above) to the metrics of interest (KCC, AUC and RMSD). We then performed an all-vs-all comparison recording the p-values, and corrected for multiple hypothesis errors using the Bonferroni method.

### Characterization of easy and hard to predict variants

We examined the mutation effects that were easiest and hardest to predict in order to determine whether they shared any common features. We first identified these mutations by summing the binary predictions (0 for no growth, >0 for growth) at low pyridoxine conditions across all methods for each variant. The variants with the lowest and highest summed scores were individually examined in terms of sequence, solvent-accessibility and location within the CBS structure.

To determine the likelihood of a variant being benign or deleterious through sequence analysis, scores for amino acid substitutions were taken from the BLOSUM90 substitution matrix (Henikoff & Henikoff, 1992). Scores of -1, 0 or 1 were classified as moderate substitutions, i.e. substitutions with a likelihood of arising by chance in terms of evolution and therefore of unknown effect on CBS function. Scores >1 were classified as conservative substitutions with a projected benign effect on CBS, while scores <-1 were classified as non-conservative, indicating a potentially deleterious effect on CBS function. Solvent accessible surface area (SASA) was calculated for the human CBS monomer (PDB id

4COO) using GetArea (Fraczkiewicz & Braun, 1998) and when different, dimer SASA results were noted. Secondary structure assignments and analysis were according to PDB id 4COO and visual inspection of the structure.

### Method uniqueness in prediction results

For CAGI2, evaluation of the specific contribution of each prediction to the variance with experimental results was addressed using a multiple linear regression model. First, a multiple linear regression model was built with the best methods from each group. The top method from each group was chosen based on the highest adjusted  $R^2$  values of every single method, to exclude predictions using modified versions of the same methods. The final methods included in the model were SID#16, 23, 26, 27, 29, 34, 36, and 41. Subsequently, methods were removed one at a time, and the linear regression equation was recalculated. The contribution of each method to the model was estimated from the delta adjusted  $R^2$  values. SID#25 was excluded from the model as it lacked predictions for 10 substitutions.

## RESULTS

### CAGI1 challenge

In the CAGI1 CBS challenge, participants were asked to submit predictions to assess the impact of 51 single amino acid substitutions upon the function of the human CBS enzyme in both high (400 ng/ml) and low (2 ng/ml) pyridoxine concentrations. The function of the variants had been experimentally tested in an *in vivo* yeast complementation assay (Dimster-Denk et al., 2013). Twenty predictions from 13 groups were submitted to this challenge (Table 2), which were assessed blindly. A summary of each method is described in Supporting Information. Of the 13 participating groups, nine submitted one prediction, two contributed two, one submitted three and one provided four different submissions. Some methods used sequence-only or structure-only information, some employed meta-predictors, and others combined sequence, structural and annotation data. SID#17 (submission identification number) submitted only raw data without predictions and was excluded from the assessment. Most participants (18/19) provided predictions for both high and low pyridoxine concentration; however, seven predictions did not distinguish between the different cofactor levels. The majority of the predictions did not include standard deviations (13/19), and most of the methods that included estimates of reliability for each prediction appeared to be arbitrary (constant values like  $\sigma=5, 10, 15$ ;  $n=5/7$ ).

**1. Assessment across different performance metrics**—No single evaluation measure can capture a method's performance; thus, various measures were used to assess the phenotype prediction programs, including Kendall's Tau correlation coefficient (KCC), precision/recall, accuracy, and root-mean-square deviation (RMSD), *inter alia* (Supp. Table S1). For KCC, most of the prediction methods display statistically significant correlation with experimental data at both pyridoxine concentrations (Figure 1). Methods SID#2, SID#5 and SID#20 showed strong correlation at both high and low cofactor concentrations. SID#7 was the second best at high pyridoxine concentration ( $\tau=0.50$ ,  $p=4.87\times 10^{-6}$ ); however, it showed little correlation at low cofactor concentration ( $\tau=0.25$ ,  $p=0.034$ ). For RMSD, SID#5, which is a meta-predictor, was the best and second best at low and high cofactor



concentration, respectively. The highest accuracy of 82.4% was achieved by three methods SID#1, 6 and 20 (Supp. Table S1). The first two combined sequence and structure information, while SID#20 is a meta-predictor, integrating several prediction methods. SID#2, 3, 9 and 11 achieved 100% sensitivity, whereas other methods had the highest specificity (94–100%, SID#7, SID#14) at both cofactor concentrations. The most sensitive models were mostly structure-based. The majority of the methods had good results for PPV, where the values varied from 65–100%; however, for NPV, the values displayed a much wider range (0–90%), meaning that the methods are better at predicting benign than deleterious variants.

**2. Overall ranking**—In order to carry out an overall performance assessment, ranks of the prediction methods based on KCC, AUC and RMSD were averaged to obtain the overall ranks of the methods (Supp. Table S2). This revealed SID#2 as the best performing method, having a mean rank of 2.2 across all measures, with SID#5 close behind (mean rank of 2.3). The first method is based on sequence information integrated with functional and structural annotations, while the other is a meta-predictor. One of the methods that did not perform as well, SID#16, was biased toward the prediction of low growth variants, whereas SID#13 was more conservative, with moderate to high growth predicted for most of the substitutions.

To estimate the robustness of the rankings, bootstrapping was performed (see Methods). Error bars for each metric were obtained by random resampling of the 51 variants 10,000 times. The rankings of the KCC, AUC and RMSD for both high and low concentrations have only minor fluctuations, indicating that the prediction models are relatively robust (Figure 1). More than half of the predictions did better than the baseline method, SIFT (SID#15), which ranked 11th overall. Statistical significance estimation was performed for the metrics of interest (KCC, AUC, and RMSD) also using bootstrap simulation. None of the methods were significantly better than SIFT for KCC and AUC after Bonferroni correction (Supp. Figure S1, S2). However for RMSD, SID#5, 11, and 20 outperformed SIFT at both cofactor concentrations even after Bonferroni correction (Supp. Figure S3).

**3. Easy and hard to predict variants**—We examined variants that were the easiest or hardest to predict based on the consensus output of all methods to determine whether they shared any common features (Figure 2B, Supp. Figure S7). At low cofactor concentration, there were overall 12% (2/17) deleterious variants and 18% (6/34) benign variants whose effects were predicted incorrectly by more than half of the methods, our definition of *consensus*.

The deleterious mutations that were easiest to predict at a low cofactor concentration were p.L154P, p.N228K, p.G258R and p.G457E. The majority of these are non-conservative substitutions and are located within helices in the CBS structure (Supp. Table S3). The easiest to predict benign variants (low pyridoxine) were p.K271E, p.V356A and p.T383S, with moderate conservation scores and were again mostly located within helices. Among the better predicted benign variants, the majority were partially or fully exposed to the solvent.

The hardest to predict deleterious variants at both high and low pyridoxine concentrations were p.H65L and p.F385Q. p.H65 is located in the H1-H2 loop and axially coordinates the



iron atom on one side of the heme plane, with C52 on the other, and mutation of either of these residues results in low catalytic activity (Ojha, Wu, LoBrutto, & Banerjee, 2002). Interestingly, the functional impact of these variants was not easy to assess from sequence and structure comparisons. Although p.H65 and the sequence flanking it are locally conserved, the heme-binding domain itself (comprising approximately the first 70 N-terminal residues), with the exception of a short 5-residue helix, has no secondary structure elements and does not resemble other heme proteins in either primary sequence or tertiary structure (Kumar et al., 2018). p.F385Q is located in the H17-H18 loop that forms part of the linker connecting the N-terminal catalytic domain with the C-terminal regulatory domain, and lies within an aromatic cluster of residues p.Y381, p.F332, p.F334, p.F385, p.W390, p.F396 enclosed by salt bridges p.R336-D388, p.K394-E302, and p.K384-E302 connecting helices H12-H14, H17, and H18. Erroneous coordination between aromatic residues can disrupt the extended  $\pi$ - $\pi$  networks formed by aromatic clusters, thereby affecting protein stability and folding (Madhusudan Makwana & Mahalakshmi, 2015). Additionally, both these variants involve non-conservative substitutions, and thus could be expected to have a deleterious effect on CBS function.

The hardest to predict benign variants (low pyridoxine) were surprising in that they involved non-conserved substitutions, so they could be expected to disrupt CBS function. Additionally, within the structure, some were implicated in functionally relevant regions of CBS, such as the dimer interface (p.L345P) and the active site (p.V118G, adjacent to the PLP-ligating p.K119). All inaccurate consensus predictions of benign variants at low pyridoxine were for variants that confer sensitivity to reduced pyridoxine levels relative to the major allele (Dimster-Denk et al., 2013). The methods that correctly predicted all of these variants (SID#2, SID#3 and SID#9) displayed a broad spread both in features used (sequence, structure and thermodynamics respectively) and in overall performance (Table 2). Additionally, SID#2 and SID#9 did not distinguish between high and low pyridoxine.

### CAGI2 challenge

In the CAGI2 CBS challenge, 84 single amino acid variants that had been observed in patients with homocystinuria were collected and functionally tested in an *in vivo* yeast complementation assay (Mayfield et al., 2012). 78 had experimental values for both pyridoxine concentrations; 6 ‘hem1 rescue’ variants were left out from the assessment due to absent/conflicting data (Table 1). Participants were again asked to submit predictions of the effect of the variants on the function of CBS both in high and low cofactor concentration. This challenge attracted 20 submissions from 9 groups (Table 2) that were assessed without knowledge of the identity of the predictors. An overview of the methods is provided in Supporting Information. Four groups submitted one submission each, three groups submitted two each, and one group each contributed four and six predictions respectively. Four groups participated in both CAGI1 and CAGI2 CBS challenges. As in CAGI1, features used to generate the predictions ranged from sequence- or structure-only information to meta-predictors and methods combining sequence, structural and functional annotation data. SID#31 was excluded from the assessment due to its constant growth rate prediction of 100 for all substitutions. Almost all groups (17/19) provided distinct values for high/low cofactor concentrations. For this challenge, most submitters also provided standard deviations

(13/19). Only one of the methods had arbitrary standard deviation values for all predictions (SID#26,  $\sigma=10$ ). In addition to prediction programs, reference results were obtained by submitting the mutations to the SNAP (SID#50) and SIFT (SID#51) public servers (Bromberg, Yachdav, & Rost, 2008; P. Kumar, Henikoff, & Ng, 2009).

**1. Assessment across different performance metrics**—The same assessment measures as in CAGI1 were used in CAGI2 (Methods). Looking at KCC, over half of the predictions were highly significant (Figure 3); however, even the best deviated substantially from experimental values. At both high and low pyridoxine concentrations, methods SID#16 and SID#26 showed the strongest correlation with the experimental data and had also high AUC values (Figure 3). The latter was also the top predictor in terms of RMSD. In terms of accuracy, a structure-based method (SID#25) had the highest value (72%) at high and low pyridoxine concentration (Supp. Table S2). At both cofactor concentrations, methods SID#16, 26, 34, and 41 had the highest sensitivity (100%). Most of these methods employed integrated sequence and structure information. SID#23 was the top method (high pyridoxine) with a 75% specificity, SID#27 and SID#28 scored 83% (low pyridoxine). SID#23 used structural data, whereas the other two are meta-predictors. In contrast to the CAGI1 CBS challenge, NPV showed higher median values than PPV (65 vs 57%), implying that the probability of loss of function was slightly better predicted than the probability of having no or minor effects on the phenotype.

**2. Overall ranking**—As in the CAGI1 CBS challenge, we computed the overall ranks representing the performance of the submissions. Based on this criterion, the top methods in the CAGI2 CBS challenge were SID#26 and SID#16 with overall ranks of 1.8 and 2.3 respectively. Both methods utilized combined evolutionary information and structural features and ranked higher than the best baseline method (SID#50). For CAGI2, random resampling of the 78 variants 10,000 times generated error bars for each metric. As in CAGI1, the overall performance ranking remained unchanged. Methods that performed well generally resulted in smaller error bars, whereas methods that had only a few correct predictions exhibited a larger variance in performance as assessed by resampling (Figure 3).

Almost all of the methods performed better than the random predictor (SID#24), with the exception of SID#32 that ranked lower according to all assessment measures at both cofactor concentrations (Supp. Table S2). SID#32 is a random forest classifier that provided only binary outputs for both concentrations (no growth or growth, with values of 0 or 100 respectively). According to the bootstrap simulation, SID#16 and 26 performed significantly better than random at high pyridoxine concentration for all metrics (Supp. Figure S4–6). Two of the baseline methods, SNAP (SID#50) and SIFT (SID#51), had an overall ranking of third and sixth, respectively. None of the methods outperformed the baseline methods for KCC and AUC after Bonferroni correction (Supp. Figure S4, 5). For RMSD on the other hand, SID#26 did significantly better than SIFT at high cofactor concentration and SID#16 outperformed SNAP at low cofactor concentration.

**3. Easy and hard to predict variants**—The hardest and easiest to predict variants (Figure 2C, Supp. Figure S82) showed similar trends to those observed in the CAGI1 CBS challenge. As observed before, the inaccurately predicted benign variants (low pyridoxine)

involved non-conservative substitutions and were located in loop regions of the CBS structure (Supp. Table S3). The most accurately predicted deleterious variants (low pyridoxine) involved a majority of non-conservative mutations of residues located within stable secondary structure elements (helices), while the hardest to predict deleterious predictions involved residues with moderate conservation scores mostly located within loops.

Within this last group, a number of mutants have been indirectly implicated in CBS function through involvement in homooligomerization, redox sensing and regulation. p.A355 lies within helix H15, which is in turn sandwiched between H4 and strand beta3 at the CBS homodimerization interface. By introducing a kink in H15, the p.A355P mutant could potentially disrupt the folding in this region of the protein thereby impacting CBS function. Similarly, p.V168 is positioned at the homodimer interface while p.M391 is located within helix H18, a region of putative involvement in CBS homotetramer formation (Ereno-Orbea, Majtan, Oyenarte, Kraus, & Martinez-Cruz, 2013). p.A288 packs against p.W323 on strand beta6, and next to it, p.F324 packs against p.A360 in helix H15. p.A361 lies within interacting distance of p.C370, a residue that has been implicated in homocystinuria (Kraus et al., 1999) and proposed to modulate CBS function through interaction with an endogenous regulator such as nitric oxide (Eto & Kimura, 2002). The p.A361T mutant could therefore potentially interfere with a functionally relevant modification (e.g. S-nitrosylation) of p.C370. Similarly, modification of p.A288 could disrupt the pairing or orientation between beta5 and beta6, thereby potentially impacting the 272-CxxC-275 oxygen sensing motif of CBS, a redox active disulfide bond that allosterically controls CBS activity (Niu et al., 2018).

The most inaccurately predicted deleterious mutant, p.E302K, lies within interacting distance of one of the two active site loops (situated between helices H6 and H7). Recent studies have highlighted the importance of conformational flexibility of the loops defining the entrance to the catalytic site (Majtan et al., 2018).

**4. Correlation between methods and unique contribution of different methods**—To have a better understanding of the strengths and weaknesses of the different methods, we investigated the correlation between their predictions (Figure 4). Correlation heatmaps for high and low pyridoxine concentration had negligible differences. The strongest predictor for method correlation appeared to be the relation to a single group (Table 2). For example, SID#27–28, SID#33&41 and all (SID#19–22) except one method (SID#23) were highly correlated among each other. However, SID#29–32 and 35–36 had higher correlations with other methods than among their own group. SID#29–32 were the only predictors that used simply two states (growth rates of 0 or 100). Interestingly, two of the best ranking methods (SID#16 and SID#26) were strongly correlated. In addition, SID# 27, 28 and 34 showed a strong correlation with the top prediction methods, although were based on different features.

Baseline methods SNAP (SID#50) and SIFT (SID#51) showed strong correlation with the best performing predictions, which is partly expected as SID#16 was based on a version of the SNAP algorithm.

In order to assess the specific contribution of each method to the variance with experimental results in CAGI2, we applied a multiple linear regression model as described in Methods above. For high pyridoxine concentration, this revealed SID#16 and SID#36 as the most significant contributors (adjusted  $R^2$  values of 0.053 and 0.041, respectively). At the same time, for low pyridoxine concentration, SID#36 and SID#27 contributed the most (0.054 and 0.053, respectively). SID#36 is based on protein structure, sequence homology and included functional information, whereas SID#16 combined evolutionary information with structural features, and SID#27 is a meta-predictor (Figure 5).

## DISCUSSION

### Prediction features in relation to performance

In terms of prediction features, different methods performed well in distinct assessment measures. We observed that methods integrating sequence and structural information performed the best overall, ranking first or second (SID#2 in CAGI1, SID#16 and SID#26 in CAGI2). Methods that used only structural information (SID#9 and 11 in CAGI1, SID#19–20 in CAGI2) did not perform as well as those combining additional features. However, in terms of individual evaluation metrics, a structure-based method showed the highest accuracy of 72% (SID#25) in CAGI2. In CAGI1, SID#1 and 20 were the best at both cofactor concentrations, reaching accuracy of 82%. The first one combined structure and sequence data while SID#20 is a meta-predictor. In terms of sensitivity, most of the top-performing methods were structure-based in CAGI1 (SID#3, SID#9, and SID#11), while in CAGI2, the most sensitive algorithms combined structure with sequence data (SID#16, SID#26, SID#34). At the same time, for specificity, almost all of the top methods were meta-predictors in CAGI2 (SID#27–28). These observations suggest that combining different features and methods would yield the best results, as has been indicated previously (Grimm et al., 2015; Tang & Thomas, 2016). Some methods are tailored to predict whether a variant affects the function of the protein in hand and others are optimized to determine whether a variant is pathogenic or benign in the clinical sense (Grimm et al., 2015; Katsonis et al., 2014; Pejaver, Mooney, & Radivojac, 2017).

The importance of integrating information from different sources is reflected in the most inaccurately predicted mutants that tended towards non-conserved substitutions, structural uncertainty, or both. The power of combining structural, sequence and functional information was visible in CAGI2, where the overall performance of a structure and sequence combined method (SID#35) was improved significantly (by five ranks) with the inclusion of functional annotation data (SID#36). The latter was also the method that uniquely contributed the most predictive power of all methods at low pyridoxine concentration. Another structure-based method (SID#25) that incorporated functional information (trained on the CAGI1 dataset) also performed strongly. Methods trained on HGMD (Human Gene Mutation Database) mutations (SID#35–36) would be expected to perform well (Dong et al., 2015; Ioannidis et al., 2016; Pejaver et al., 2017). Interestingly, however, the best methods in CAGI2 CBS challenge showed variable training data, from no training to training on PMD (the Protein Mutant Database), HGMD, and CAGI1 CBS variant data (Supporting Information).

## Limitations of the challenges

In terms of methodological limitations, most methods were developed to predict pathogenicity in humans or enzyme activity, not yeast growth or the effect of cofactor concentration on growth rate, something that could at least in part explain the difficulties they encountered in identifying the remediable class of variants (Supporting Information). So, while a meaningful distinction could be made in these challenges between growth and no growth under low pyridoxine conditions, this was not the case for distinguishing between rescue (high pyridoxine) and no rescue (low pyridoxine) variants. Similarly, only qualitative comparisons could be made between CAGI1 and CAGI2, since the datasets differed in size and type, and only four groups participated in both challenges. Among these, one group used different versions of their method (SID#1 in CAGI1, and SID#26 in CAGI2), while two others did not make use of the CBS training data.

Another limitation of the assessment involved requesting standard deviation as estimates of reliability from predictors, as opposed to the more commonly employed confidence levels that most prediction methods provide. Consequently, some predictors did not provide these values, chose them arbitrarily, or provided large values with the result that they could not be reasonably used in these assessments.

These challenges also revealed a number of experimental limitations. Yeast CBS lacks the heme domain and is not regulated by AdoMet (Jhee, McPhie, & Miles, 2000), thereby engaging different pathways in the enzyme's regulation and physiological roles. Additionally, over-expression can result in non-physiological effects, including protein aggregation. These differences could help explain some of the inconsistencies observed in the experimental study in which yeast growth phenotypes did not match the clinical data (Mayfield et al., 2012). Although, only three positions from the heme domain were part of these two CBS challenges, with merely one position being problematic for the predictors (Figure 2). In a similar study, several variants identical to the ones used in these experiments resulted in contrasting yeast growth phenotypes (Wei, Wang, Wang, Kruger, & Dunbrack, 2010).

In addition, the clinical assessment of the majority of variants explored in this study has since changed. Of the 78 alleles described in CAGI2 as having been observed in patients with homocystinuria, only 30 are currently classified as pathogenic or likely pathogenic in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>, accessed March 25, 2019), with an additional 16 annotated as being of uncertain significance or with conflicting interpretations of pathogenicity (Table 1). Eight substitutions (p.P78R, p.K102N, p.D234N, p.R266K, p.V320A, p.T353M, p.V371M, p.D444N) out of 22 that showed experimental growth rates of ~85% in CAGI2 are currently annotated as pathogenic or likely pathogenic. Most of the participants made accurate predictions for these 'benign' variants (Figure 2). It is important to mention here that ClinVar had not yet been launched during the first two CAGI challenges. Also, not all the (likely) pathogenic CBS variants currently present in ClinVar have been collected from clinical testing, some are based on literature with no assertion criteria provided. Ideally, different functional assays should be applied, in order to increase the confidence in the observed phenotypic effect of the studied variant, because the function of a gene can differ in distinct organisms. Finally, mutations in *cis* with the ability to either

suppress other pathogenic missense mutations or increase the severity of the clinical phenotype continue to be reported (de Franchis, Kraus, Kozich, Sebastio, & Kraus, 1999; Shan, Dunbrack, Christopher, & Kruger, 2001), raising the possibility that the incidence of double mutant alleles may be underestimated in homocystinuric patients.

## Conclusion

CBS is a multi-functional enzyme with complex biology and intricate regulation that remains the object of much study. Our assessment of the CAGI1 and CAGI2 CBS challenges highlighted the strengths and weaknesses of different prediction features and approaches, as well as the need to address issues of methodological and experimental limitations. Both computational and experimental methods need to be tailored to the particular biological question under investigation in order to improve the predictive potential of the variant effect. It is hoped that future iterations of CAGI will see improvements on all these fronts.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

The authors are grateful to the CAGI organizers, data providers, participants, and would like to thank Pauline C. Ng for her contribution in the initial analysis of CAGI1. The CAGI experiment coordination is supported by NIH U41 HG007346 and the CAGI conference by NIH R13 HG006650.

Funding information National Institutes of Health, Grant/Award Numbers: R01 GM120374, R01 GM079656, R01 LM009722, R01 GM071749, R13 HG006650, R01 GM114434, R01 GM066099, U01 GM115486, U41 HG007346; Fondazione Istituto di Ricerca Pediatrica – città della Speranza, Grant/Award Number: 18-04; Estonian Research Council, Grant/Award Number: IUT34-12; Marie Curie International Outgoing Fellowship, Grant/Award Number: PIOF-GA-2009-237751; The Ministry of Education, Universities and Research (MIUR), Grant/Award Number: FFABR grant; Italian Ministry of Health, Grant/Award Number: GR-2011-02347754; The Interuniversity Attraction Pole (IAP) Network from the Science Policy of the Federal Government of Belgium (Belspo), Grant/Award Number: P7/16; National Science Foundation, Grant/Award Number: ABI 1458359; The University of Leuven (KUL); Flanders Institute for Biotechnology (VIB); The Flanders Institute for Science and Technology (IWT) (PhD grant to GDB); The Funds for Scientific Research Flanders (FWO), Grant/Award Number: G.0509.13

## References

- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, ... Sunyaev SR (2010). A method and server for predicting damaging missense mutations. *Nat Methods*, 7(4), 248–249. doi:10.1038/nmeth0410-248 [PubMed: 20354512]
- Bromberg Y, & Rost B (2007). SNAP: predict effect of non-synonymous polymorphisms on function. *Nucleic Acids Res*, 35(11), 3823–3835. doi:10.1093/nar/gkm238 [PubMed: 17526529]
- Capriotti E, Fariselli P, Rossi I, & Casadio R (2008). A three-state prediction of single point mutations on protein stability changes. *BMC Bioinformatics*, 9 Suppl 2, S6. doi:10.1186/1471-2105-9-S2-S6
- de Franchis R, Kraus E, Kozich V, Sebastio G, & Kraus JP (1999). Four novel mutations in the cystathionine beta-synthase gene: effect of a second linked mutation on the severity of the homocystinuric phenotype. *Hum Mutat*, 13(6), 453–457. doi:10.1002/(SICI)1098-1004(1999)13:6<453::AID-HUMU4>3.0.CO;2-K [PubMed: 10408774]
- Dimster-Denk D, Tripp KW, Marini NJ, Marqusee S, & Rine J (2013). Mono and dual cofactor dependence of human cystathionine beta-synthase enzyme variants in vivo and in vitro. *G3 (Bethesda)*, 3(10), 1619–1628. doi:10.1534/g3.113.006916 [PubMed: 23934999]




- Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, & Liu X (2015). Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. *Hum Mol Genet*, 24(8), 2125–2137. doi:10.1093/hmg/ddu733 [PubMed: 25552646]
- Ereno-Orbea J, Majtan T, Oyenarte I, Kraus JP, & Martinez-Cruz LA (2013). Structural basis of regulation and oligomerization of human cystathionine beta-synthase, the central enzyme of transsulfuration. *Proc Natl Acad Sci U S A*, 110(40), E3790–3799. doi:10.1073/pnas.1313683110 [PubMed: 24043838]
- Eto K, & Kimura H (2002). A novel enhancing mechanism for hydrogen sulfide-producing activity of cystathionine beta-synthase. *J Biol Chem*, 277(45), 42680–42685. doi:10.1074/jbc.M205835200 [PubMed: 12213817]
- Fernald GH, Capriotti E, Daneshjou R, Karczewski KJ, & Altman RB (2011). Bioinformatics challenges for personalized medicine. *Bioinformatics*, 27(13), 1741–1748. doi:10.1093/bioinformatics/btr295 [PubMed: 21596790]
- Fraczkiewicz R, & Braun W (1998). Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. *Journal of Computational Chemistry*, 19(3), 319–333. doi:10.1002/(sici)1096-987x(199802)19:3<319::aid-jcc6>3.0.co;2-w
- Grimm DG, Azencott CA, Aicheler F, Gieraths U, MacArthur DG, Samocha KE, ... Borgwardt KM. (2015). The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity. *Hum Mutat*, 36(5), 513–523. doi:10.1002/humu.22768 [PubMed: 25684150]
- Henikoff S, & Henikoff JG (1992). Amino acid substitution matrices from protein blocks. *Proc Natl Acad Sci U S A*, 89(22), 10915–10919. doi:10.1073/pnas.89.22.10915 [PubMed: 1438297]
- Hoskins RA, Repo S, Barsky D, Andreoletti G, Moul J, & Brenner SE (2017). Reports from CAGI: The Critical Assessment of Genome Interpretation. *Hum Mutat*, 38(9), 1039–1041. doi:10.1002/humu.23290 [PubMed: 28817245]
- Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, ... Sieh W. (2016). REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet*, 99(4), 877–885. doi:10.1016/j.ajhg.2016.08.016 [PubMed: 27666373]
- Jhee KH, McPhie P, & Miles EW (2000). Yeast cystathionine beta-synthase is a pyridoxal phosphate enzyme but, unlike the human enzyme, is not a heme protein. *J Biol Chem*, 275(16), 11541–11544. doi:10.1074/jbc.C000056200 [PubMed: 10766767]
- Katsonis P, Koire A, Wilson SJ, Hsu TK, Lua RC, Wilkins AD, & Lichtarge O (2014). Single nucleotide variations: biological impact and theoretical interpretation. *Protein Sci*, 23(12), 1650–1666. doi:10.1002/pro.2552 [PubMed: 25234433]
- Katsonis P, & Lichtarge O (2014). A formal perturbation equation between genotype and phenotype determines the Evolutionary Action of protein-coding variations on fitness. *Genome Res*, 24(12), 2050–2058. doi:10.1101/gr.176214.114 [PubMed: 25217195]
- Kraus JP, Janosik M, Kozich V, Mandell R, Shih V, Sperandio MP, ... Gaustadnes M. (1999). Cystathionine beta-synthase mutations in homocystinuria. *Hum Mutat*, 13(5), 362–375. doi:10.1002/(SICI)1098-1004(1999)13:5<362::AID-HUMU4>3.0.CO;2-K [PubMed: 10338090]
- Kumar A, Wissbrock A, Goradia N, Bellstedt P, Ramachandran R, Imhof D, & Ohlenschlager O (2018). Heme interaction of the intrinsically disordered N-terminal peptide segment of human cystathionine-beta-synthase. *Sci Rep*, 8(1), 2474. doi:10.1038/s41598-018-20841-z [PubMed: 29410458]
- Kumar P, Henikoff S, & Ng PC (2009). Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc*, 4(7), 1073–1081. doi:10.1038/nprot.2009.86 [PubMed: 19561590]
- Lever J, Krzywinski M, & Altman N (2016). Classification evaluation. *Nature Methods*, 13, 603. doi:10.1038/nmeth.3945
- Madhusudan Makwana K, & Mahalakshmi R (2015). Implications of aromatic-aromatic interactions: From protein structures to peptide models. *Protein Sci*, 24(12), 1920–1933. doi:10.1002/pro.2814 [PubMed: 26402741]
- Majtan T, Pey AL, Gimenez-Mascarell P, Martinez-Cruz LA, Szabo C, Kozich V, & Kraus JP (2018). Potential Pharmacological Chaperones for Cystathionine Beta-Synthase-Deficient




- Homocystinuria. *Handb Exp Pharmacol*, 245, 345–383. doi:10.1007/164\_2017\_72 [PubMed: 29119254]
- Mayfield JA, Davies MW, Dimster-Denk D, Pleskac N, McCarthy S, Boydston EA, ... Rine J. (2012). Surrogate genetics and metabolic profiling for characterization of human disease alleles. *Genetics*, 190(4), 1309–1323. doi:10.1534/genetics.111.137471 [PubMed: 22267502]
- Moat SJ, Bao L, Fowler B, Bonham JR, Walter JH, & Kraus JP (2004). The molecular basis of cystathionine beta-synthase (CBS) deficiency in UK and US patients with homocystinuria. *Hum Mutat*, 23(2), 206. doi:10.1002/humu.9214
- Moorthie S, Cameron L, Sagoo GS, Bonham JR, & Burton H (2014). Systematic review and meta-analysis to estimate the birth prevalence of five inherited metabolic diseases. *J Inherit Metab Dis*, 37(6), 889–898. doi:10.1007/s10545-014-9729-0 [PubMed: 25022222]
- Mudd SH, Levy HL, & Kraus JP (2001). Disorders of transsulfuration In Scriver CR, Beaudet A, Sly W, & Valle D (Eds.), *The Metabolic Basis of Inherited Disease* (pp. 2007–2056): McGraw-Hill, New York.
- Niu W, Wang J, Qian J, Wang M, Wu P, Chen F, & Yan S (2018). Allosteric control of human cystathionine beta-synthase activity by a redox active disulfide bond. *J Biol Chem*, 293(7), 2523–2533. doi:10.1074/jbc.RA117.000103 [PubMed: 29298893]
- Ojha S, Wu J, LoBrutto R, & Banerjee R (2002). Effects of heme ligand mutations including a pathogenic variant, H65R, on the properties of human cystathionine beta-synthase. *Biochemistry*, 41(14), 4649–4654. [PubMed: 11926827]
- Olatubosun A, Valiaho J, Harkonen J, Thusberg J, & Vihinen M (2012). PON-P: integrated predictor for pathogenicity of missense variants. *Hum Mutat*, 33(8), 1166–1174. doi:10.1002/humu.22102 [PubMed: 22505138]
- Pejaver V, Mooney SD, & Radivojac P (2017). Missense variant pathogenicity predictors generalize well across a range of function-specific prediction challenges. *Hum Mutat*, 38(9), 1092–1108. doi:10.1002/humu.23258 [PubMed: 28508593]
- Pey AL, Majtan T, Sanchez-Ruiz JM, & Kraus JP (2013). Human cystathionine beta-synthase (CBS) contains two classes of binding sites for S-adenosylmethionine (SAM): complex regulation of CBS activity and stability by SAM. *Biochem J*, 449(1), 109–121. doi:10.1042/BJ20120731 [PubMed: 22985361]
- Rost B, Radivojac P, & Bromberg Y (2016). Protein function in precision medicine: deep understanding with machine learning. *FEBS Lett*, 590(15), 2327–2341. doi:10.1002/1873-3468.12307 [PubMed: 27423136]
- Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, & Serrano L (2005). The FoldX web server: an online force field. *Nucleic Acids Res*. 33(Web Server issue), W382–8. doi: 10.1093/nar/gki387 [PubMed: 15980494]
- Shan X, Dunbrack RL Jr., Christopher SA, & Kruger WD (2001). Mutations in the regulatory domain of cystathionine beta synthase can functionally suppress patient-derived mutations in cis. *Hum Mol Genet*, 10(6), 635–643. doi:10.1093/hmg/10.6.635 [PubMed: 11230183]
- Skovby F, Gaustadnes M, & Mudd SH (2010). A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. *Mol Genet Metab*, 99(1), 1–3. doi:10.1016/j.ymgme.2009.09.009 [PubMed: 19819175]
- Skovby F, Kraus JP, & Rosenberg LE (1984). Biosynthesis and proteolytic activation of cystathionine beta-synthase in rat liver. *J Biol Chem*, 259(1), 588–593. [PubMed: 6706953]
- Zou CG, & Banerjee R (2003). Tumor necrosis factor-alpha-induced targeted proteolysis of cystathionine beta-synthase modulates redox homeostasis. *J Biol Chem*, 278(19), 16802–16808. doi:10.1074/jbc.M212376200 [PubMed: 12615917]
- Tang H, & Thomas PD (2016). Tools for Predicting the Functional Impact of Nonsynonymous Genetic Variation. *Genetics*, 203(2), 635–647. doi:10.1534/genetics.116.190033 [PubMed: 27270698]
- Tavtigian SV, Byrnes GB, Goldgar DE, & Thomas A (2008). Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. *Hum Mutat*, 29(11), 1342–1354. doi:10.1002/humu.20896 [PubMed: 18951461]
- Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A, & Lazareva-Ulitsky B (2006). Applications for protein sequence-function evolution data: mRNA/protein expression analysis and

coding SNP scoring tools. *Nucleic Acids Res*, 34(Web Server issue), W645–650. doi:10.1093/nar/gkl229 [PubMed: 16912992]


- Weeks CL, Singh S, Madzellan P, Banerjee R, & Spiro TG (2009). Heme regulation of human cystathionine beta-synthase activity: insights from fluorescence and Raman spectroscopy. *J Am Chem Soc*, 131(35), 12809–12816. doi:10.1021/ja904468w [PubMed: 19722721]
- Wei Q, Wang L, Wang Q, Kruger WD, & Dunbrack RL Jr. (2010). Testing computational prediction of missense mutation phenotypes: functional characterization of 204 mutations of human cystathionine beta synthase. *Proteins*, 78(9), 2058–2074. doi:10.1002/prot.22722 [PubMed: 20455263]
- Ye ZQ, Zhao SQ, Gao G, Liu XQ, Langlois RE, Lu H, & Wei L (2007). Finding new structural and sequence attributes to predict possible disease association of single amino acid polymorphism (SAP). *Bioinformatics*, 23(12), 1444–1450. doi:10.1093/bioinformatics/btm119 [PubMed: 17384424]
- Yoo J, Lee Y, Kim Y, Rha SY, & Kim Y (2008). SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. *BMC Bioinformatics*, 9, 290. doi:10.1186/1471-2105-9-290 [PubMed: 18570686]
- Yue P, & Moulton J (2006). Identification and analysis of deleterious human SNPs. *J Mol Biol*, 356(5), 1263–1274. doi:10.1016/j.jmb.2005.12.025 [PubMed: 16412461]
- [dataset] CAGI; 2010/2011; CBS challenge dataset; Dataset available to registered users from the CAGI web site: <https://genomeinterpretation.org/content/cagi-2011-results>.




**Figure 1.** Kendall’s Tau correlation coefficient (KCC), area under the ROC curve (AUC) and root-mean-square deviation (RMSD) for the phenotype prediction programs at high (black) and low (grey) cofactor concentration in the CAGI1 CBS challenge. Statistical significance of correlation scores is indicated with asterisks (\* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001). Error bars represent one standard deviation below and above the mean value for each metric generated through iterations of bootstrap sampling of data-points.




**Figure 2.** Consensus predictions for CBS. (A) CBS domain diagram, (B) CAGI1, (C) CAGI2. The percentage of correct predictions for deleterious (red) and benign (blue) variants is shown for each experimentally determined variant at low pyridoxine concentration. Residues are shaded in the color of the corresponding domain, with the linker region highlighted in orange.



**Figure 3.** Kendall’s Tau correlation coefficient (KCC), area under the ROC curve (AUC) and root-mean-square deviation (RMSD) for the phenotype predictions at high (black) and low (grey) cofactor concentration in the CAGI2 CBS challenge. Statistical significance of correlation scores is indicated with asterisks (\* P 0.05, \*\* P 0.01, \*\*\* P 0.001). Error bars represent one standard deviation below and above the mean value for each metric generated through iterations of bootstrap sampling of data-points.



**Figure 4.** Spearman’s rank correlation among methods and with experimental data (Exp) for high and low cofactor concentration. Each cell shows the correlation between two methods, with a color scale ranging from red (perfect correlation) to white (no correlation) and blue (perfect anti-correlation).



**Figure 5.** adjusted  $R^2$  values of the methods from the linear regression model for high and low cofactor concentration, quantifying the contribution of each method to the proportion of total variance explained.



**Table 1.**

CAG11 prediction dataset: 51 single amino acid substitutions within the human CBS coding region. CAG12 prediction dataset: 78 single amino acid variants that had been observed in patients with homocystinuria. Current (2019) ClinVar pathogenic (P) or likely pathogenic (LP) status of the CAG12 variants in relation to homocystinuria are shown. C denotes conflicting interpretations of pathogenicity, U uncertain significance.

CAG11		CAG12		
Nucleotide variant	Protein variant	Nucleotide variant	Protein variant	ClinVar (2019)
c.194A>T	p.H65L	c.194A>G	p.H65R	
c.250A>G	p.I84V	c.205G>C	p.A69P	
c.353T>G	p.V118G	c.209C>T	p.P70L	U
c.370C>G	p.L124V	c.233C>G	p.P78R	LP
c.370 C>G, c.371T>C	p.L124A	c.253G>C	p.G85R	
c.379A>G	p.I127V	c.260C>A	p.T87N	
c.424A>G	p.I142V	c.262C>T	p.P88S	
c.424A>G,c.425T>C	p.I142A	c.302T>C	p.L101P	P/LP
c.425T>A	p.I142N	c.304A>C	p.K102Q	
c.460C>G, c.461T>C	p.L154A	c.306G>C	p.K102N	LP
c.461T>C	p.L154P	c.325T>C	p.C109R	P/LP
c.529A>G	p.K177E	c.341C>T	p.A114V	P/LP
c.541C>G, c.542T>C	p.L181A	c.346G>A	p.G116R	LP
c.562A>G	p.I188V	c.361C>T	p.R121C	C
c.566T>C	p.V189A	c.362G>A	p.R121H	LP
c.629T>A	p.L210Q	c.362G>T	p.R121L	
c.640A>G	p.I214V	c.376A>G	p.M126V	
c.659T>G	p.L220R	c.384G>T	p.E128D	
c.684C>A	p.N228K	c.393G>C	p.E131D	U
c.718A>G	p.I240V	c.415G>A	p.G139R	P
c.718A>G, c.719T>C	p.I240A	c.429C>G	p.I143M	
c.721C>G	p.L241V	c.430G>A	p.E144K	P/LP
c.742C>G, c.743T>C	p.L248A	c.434C>T	p.P145L	P
c.755T>C	p.V252A	c.442G>C	p.G148R	LP
c.772G>C	p.G258R	c.451G>A	p.G151R	
c.800A>T	p.K267M	c.457G>C	p.G153R	U
c.799A>G	p.K267E	c.461T>A	p.L154Q	
c.811A>G	p.K271E	c.463G>A	p.A155T	
c.829A>C, c.830T>C	p.I277P	c.473C>T	p.A158V	
c.839T>C	p.V280A	c.494G>A	p.C165Y	P
c.856A>G, c.857T>C	p.I286A	c.502G>A	p.V168M	C
c.877C>G	p.L293V	c.539T>C	p.V180A	U
c.931A>G	p.I311V	c.572C>T	p.T191M	P
c.1012C>G, c.1013T>C	p.L338A	c.593A>T	p.D198V	
c.1023A>T	p.Q341H	c.671G>A	p.R224H	

CAG11		CAG12		
Nucleotide variant	Protein variant	Nucleotide variant	Protein variant	ClinVar (2019)
c.1034T>C	p.L345P	c.676G>A	p.A226T	LP
c.1061T>G	p.V354G	c.683A>G	p.N228S	U
c.1067T>C	p.V356A	c.684C>A	p.N228K	
c.1073T>C	p.V358A	c.700G>A	p.D234N	P
c.1112T>C	p.V371A	c.715G>A	p.E239K	
c.1115T>C	p.V372A	c.770C>T	p.T257M	P/LP
c.1120C>G, c.1121T>C	p.L374A	c.775G>A	p.G259S	U
c.1147A>T	p.T383S	c.785C>T	p.T262M	P/LP
c.1153T>C, c.1154T>A, c.1155C>A	p.F385Q	c.796A>G	p.R266G	
c.1153T>C	p.F385L	c.797G>A	p.R266K	P/LP
c.1223G>T	p.W408L	c.824G>A	p.C275Y	
c.1268T>C	p.L423P	c.833T>C	p.I278T	P
c.1298A>T	p.H433L	c.862G>A	p.A288T	U
c.1370G>A	p.G457E	c.862G>C	p.A288P	
c.1468A>C	p.I490L	c.904G>A	p.E302K	LP
c.1646A>G	p.D549G	c.919G>A	p.G307S	P
		c.959T>C	p.V320A	LP
		c.992C>A	p.A331E	LP
		c.992C>T	p.A331V	
		c.1007G>A	p.R336H	LP
		c.1039G>A	p.G347S	LP
		c.1046G>A	p.S349N	
		c.1055G>A	p.S352N	
		c.1058C>T	p.T353M	P/LP
		c.1060G>A	p.V354M	
		c.1063G>C	p.A355P	
		c.1081G>A	p.A361T	
		c.1105C>T	p.R369C	U
		c.1106G>A	p.R369H	U
		c.1106G>C	p.R369P	
		c.1109G>A	p.C370Y	LP
		c.1111G>A	p.V371M	LP
		c.1126G>A	p.D376N	
		c.1150A>G	p.K384E	P
		c.1173G>A	p.M391I	
		c.1265C>T	p.P422L	U
		c.1301C>A	p.T434N	U
		c.1304T>C	p.I435T	U
		c.1316G>A	p.R439Q	C
		c.1330G>A	p.D444N	P/LP
		c.1367T>C	p.L456P	

<b>CAG11</b>		<b>CAG12</b>		
<b>Nucleotide variant</b>	<b>Protein variant</b>	<b>Nucleotide variant</b>	<b>Protein variant</b>	<b>ClinVar (2019)</b>
		c.1397C>T	p.S466L	U
		c.1572C>A	p.Q526K	

Positions are based on Refseq NM\_000071.2.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2.**

Overview of the phenotype prediction programs used to generate predictions for the CAGI1 and CAGI2 CBS challenges

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Submission ID	Group ID	Program name	Program features	Reference
<i>CAG11</i>				
SID#1	Lichtarge lab	Evolutionary Action working version	sequence, structure	
SID#2	Bromberg lab	SNAP	sequence, structure, annotation	Bromberg et al., 2007
SID#3	Wei lab	SAPRED	structure	Ye et al., 2007
SID#4	Switch lab	FoldX	structure	Schymkowitz et al., 2005
SID#5	Vihinen lab	PON-P	meta-predictor	Olatubosun, Valiaho, Harkonen, Thusberg, & Vihinen, 2012
SID#6	Vihinen lab	PolyPhen2	sequence, structure	Adzhubei et al., 2010
SID#7	Vihinen lab	SNPanalyzer	sequence	Yoo, Lee, Kim, Rha, & Kim, 2008
SID#8	Vihinen lab	Panther	sequence	Thomas et al., 2006
SID#9	Casadio lab	IMutant3	structure, thermal stability	Capriotti, Fariselli, Rossi, & Casadio, 2008
SID#10	Casadio lab	IMutant4	structure, thermal stability	
SID#11	Casadio lab	IMutant baseline	structure, thermal stability	
SID#12	Forman lab	SDM	sequence, structure	
SID#13	BioFold Unit	IMutant3	sequence, structure	Capriotti et al., 2008
SID#14	Karchin lab		sequence, structure	
SID#16	Mooney lab		meta-predictor	
SID#18	Forman lab	SDM	sequence, structure	
SID#19	Tavtigian lab	AlignGVGD	sequence	Tavtigian, Byrnes, Goldgar, & Thomas, 2008
SID#20	Tavtigian lab	AlignGVGD	meta-predictor	
<i>CAG12</i>				
SID#16	Bromberg lab	SNAP	sequence, structure	Bromberg et al., 2007
SID#19	Tosatto lab		structure	
SID#20	Tosatto lab		structure	
SID#21	Tosatto lab		structure	
SID#22	Tosatto lab		structure	
SID#23	Tosatto lab		structure	
SID#24	Tosatto lab	D100 roll	random	
SID#25	Switch lab		structure	
SID#26	Lichtarge Lab	Evolutionary Action	sequence, structure	Katsonis & Lichtarge, 2014
SID#27	Vihinen lab	PON-P	meta-predictor	Olatubosun et al., 2012
SID#28	Vihinen lab	PON-P	meta-predictor	Olatubosun et al., 2012
SID#29	Shatsky lab		meta-predictor	
SID#30	Shatsky lab		meta-predictor	
SID#32	Shatsky lab		meta-predictor	
SID#33	Mooney lab		meta-predictor	
SID#34	Sunyayev lab		sequence, structure	
SID#35	Moult lab	SNPs3D SVM	sequence, structure	Yue & Moult, 2006
SID#36	Moult lab	SNPs3D SVM	sequence, structure, annotation	
SID#41	Mooney lab		meta-predictor	